Assess whether to drop a secondary endpoint that will dominate the AdCom

SITUATION To drop a secondary sits with CMC change-control owner because a literature paper the 505(b)(2) package leans on getting retracted hit a mid-size sponsor after a complete response letter. Evidence is RWE protocol that may not meet regulator expectations; write the Pharma & Life Sciences Pharmacovigilance option that extract can carry.

DECISION CMC change-control owner in a mid-size sponsor after a complete response letter must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using RWE protocol that may not meet regulator expectations after a literature paper the 505(b)(2) package leans on getting retracted.

HYPOTHESES TO TEST 1. Authorize Proceed under protocol now; RWE protocol that may not meet regulator expectations already has the discriminator after a literature paper the 505(b)(2) package leans on getting retracted. 2. Keep Pause the pathway in force until RWE protocol that may not meet regulator expectations is completed after a literature paper the 505(b)(2) package leans on getting retracted for CMC change-control owner. 3. Treat RWE protocol that may not meet regulator expectations as Escalate safety review because both readings appear after a literature paper the 505(b)(2) package leans on getting retracted. 4. Refuse a Pharma & Life Sciences close: CMC change-control owner does not have the page to drop a secondary turns on in RWE protocol that may not meet regulator expectations.

ANALYSIS REQUIRED 1. Trace CMC, labeling, or pharmacovigilance facts in RWE protocol that may not meet regulator expectations after a literature paper the 505(b)(2) package leans on getting retracted. 2. Separate an isolated adverse event from a systemic quality issue. 3. Test a protocol deviation versus a safety signal versus a filing gap on to drop a secondary. 4. For this Pharma & Life Sciences Pharmacovigilance file, read RWE protocol that may not meet regulator expectations against a literature paper the 505(b)(2) package leans on getting retracted and write the one fact that would move to drop a secondary for CMC change-control owner.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / Pharmacovigilance packet (RWE protocol that may not meet regulator expectations after a literature paper the 505(b)(2) package leans on getting retracted). The follow-on Pharmacovigilance action is what CMC change-control owner does next: implement the option, assign an owner, and log the missing fact.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on to drop a secondary, then the evidence in RWE protocol that may not meet regulator expectations, then the action for CMC change-control owner - Hypothesis scorecard against RWE protocol that may not meet regulator expectations: supported / rejected / untestable - Pharmacovigilance finding in RWE protocol that may not meet regulator expectations that a second reviewer can re-perform - Missing page in RWE protocol that may not meet regulator expectations after a literature paper the 505(b)(2) package leans on getting retracted, if any